Pasireotide Diaspartate and Acarbose: Interaction Details
AI-assisted, pharmacist-reviewed · AI content regenerated Jul 11, 2026 · Source data updated Jul 10, 2026 · Sources: FDA labeling, DDInter 2.0, cited literature
Acarbose
Pasireotide Diaspartate
No brand names on record
How we grade severity & evidence
Severity levels
- Contraindicated: These should generally not be used together.
- Major: Potentially serious — often needs a change or close monitoring.
- Moderate: Can be significant — usually manageable with monitoring.
- Minor: Usually limited clinical impact.
Evidence grades
- Established: Well documented — supported by controlled studies or strong clinical data.
- Probable: Good supporting evidence, though not definitively proven.
- Suspected: Some evidence suggests this interaction, but it is not well established.
- Possible: Limited or conflicting evidence; the interaction may occur.
- Theoretical: Predicted from the drugs' pharmacology; not yet confirmed in people.
Ratings come from the documented interaction literature and are reviewed by a pharmacist. They describe the documented risk of the combination, not what will necessarily happen to you — your dose, timing, and health picture all matter.
You've been prescribed acarbose (a diabetes pill that slows how fast your body absorbs sugar from food) along with pasireotide. Pasireotide can change how your body handles blood sugar because it lowers both insulin and glucagon, two hormones that control glucose. Most often this pushes blood sugar up, but it can also make your levels harder to predict, so swings in either direction are possible.
The good news is this is very manageable. Your care team can fine-tune your diabetes treatment and check your blood sugar more often, especially when you're first starting pasireotide. Please talk with your doctor or pharmacist before changing anything on your own.
Effect: Additive disruption of glucose regulation when combining acarbose with pasireotide (a somatostatin analog).
- Mechanism: Pasireotide inhibits secretion of both insulin and glucagon, impairing glucose homeostasis; predominant clinical effect is hyperglycemia, though dysregulation in either direction may occur. Acarbose blunts postprandial glucose but does not itself cause hypoglycemia in monotherapy.
- Direction/magnitude: Unpredictable glycemic control; severe hyperglycemia possible. Neither agent is a prodrug; interaction is PD, not PK.
- Onset: Unspecified. Evidence: Theoretical. Severity: Major.
- Management: Optimize antidiabetic therapy before initiating pasireotide; individualize antidiabetic dosing and increase frequency of glucose monitoring.
What happens
An increased risk of hypoglycemia and impaired glucose regulation
Interaction Deep Dive
The secretion of both insulin and glucagon is suppressed by somatostatin analogs 3. This can result in severe elevations of blood glucose. In patients whose diabetes is poorly controlled, antidiabetic therapy should be optimized before initiating the somatostatin analog 4. It may become necessary to adjust the dose of the antidiabetic medication and to monitor glucose more frequently 125.
Why it happens (mechanism)
Altered glucose metabolism
How to manage this interaction
Keep taking both medications exactly as prescribed unless your care team tells you otherwise. Here is how a care team typically handles this combination:
- Before starting pasireotide, your team may work to get your diabetes well controlled first.
- Your acarbose dose may be adjusted and individualized by your care team based on how your glucose responds.
- Expect more frequent blood sugar checks, especially in the early weeks.
Contact your pharmacist or doctor if you notice higher-than-usual readings, unusual thirst or urination, or any symptoms of low blood sugar. Report these so your treatment can be tailored.
Management is individual — confirm any change with your pharmacist or prescriber.
Common questions
Can I take Pasireotide Diaspartate and Acarbose together?
Pasireotide can disrupt your blood sugar control (usually raising it) when taken with acarbose, so your care team will likely adjust your diabetes treatment and monitor your glucose more closely. Keep taking both as prescribed and report unusual readings. Always confirm with your pharmacist or prescriber before making any change.
How serious is the Pasireotide Diaspartate and Acarbose interaction?
It is rated major. Potentially serious — often needs a change or close monitoring.
How quickly could this interaction happen?
The documented onset is "unspecified". The timing of this interaction is not well characterized.
How is the Pasireotide Diaspartate and Acarbose interaction managed?
Keep taking both medications exactly as prescribed unless your care team tells you otherwise. Here is how a care team typically handles this combination: Before starting pasireotide, your team may work to get your diabetes well controlled first. Your acarbose dose may be adjusted and individualized by your care team based on how your glucose responds. Expect more frequent blood sugar checks, espec… Management is individual — always follow your own care team's guidance.
How strong is the evidence for this interaction?
The evidence is graded "theoretical". Predicted from the drugs' pharmacology; not yet confirmed in people.
Questions for your pharmacist
- Does my dose of Pasireotide Diaspartate or Acarbose need adjusting while I take them together?
- What symptoms should prompt me to call you or my prescriber right away?
- Does the timing of my doses matter for this combination?
- Is there a safer alternative to one of these medications for me?
References (5)
- Product Information: TOUJEO(R) subcutaneous injection, insulin glargine subcutaneous injection. sanofi-aventis (per manufacturer), Bridgewater, NJ, 2015. DailyMed
- Product Information: Tresiba subcutaneous injection solution, insulin degludec subcutaneous injection solution. Novo Nordisk A/S (per EMA), Bagsvaerd, Denmark, 2013. DailyMed
- Product Information: Sandostatin(R) LAR Depot intramuscular injection suspension, octreotide acetate intramuscular injection suspension. Novartis Pharmaceuticals Corporation (per FDA), East Hanover, NJ, 2014.
- Product Information: SIGNIFOR(R) LAR intramuscular injection suspension, pasireotide intramuscular injection suspension. Novartis Pharmaceuticals Corporation (per FDA), East Hanover, NJ, 2014.
- Product Information: ADMELOG(R) subcutaneous, intravenous injection, insulin lispro subcutaneous, intravenous injection. sanofi-aventis US LLC (per DailyMed), Bridgewater, NJ, 2023. DailyMed
Keep reading about Acarbose
Keep reading about Pasireotide Diaspartate
These medications also interact with supplements
Prescription drugs aren't the whole picture — herbal and dietary supplements can interact with them too. From the evidence-graded Natural Medicines database:
major · moderate · minor — check everything you take with our drug–supplement interaction checker.
Check another combination
Our instant two-drug interaction checker is almost here.
Still have questions about this combination?
Every question gets a real answer from a licensed pharmacist — free, and usually within a day.
Ask the pharmacist